Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Michael Durci"'
Autor:
Jacob Eckstein, MD, J. Isabelle Choi, MD, Alicia Lozano, MS, Nitin Ohri, MD, Robert Press, MD, Shaakir Hasan, DO, Rafi Kabarriti, MD, John Chang, MD, James Urbanic, MD, Michael Durci, MD, Nasiruddin Mohammed, MD, Craig Stevens, MD, PhD, Henry Tsai, MD, Smith Apisarnthanarax, MD, William Regine, MD, Carlos Vargas, MD, Romaine Nichols, Jr, MD, Joseph Herman, MD, Charles B. Simone, II, MD, Arpit Chhabra, MD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 5, Pp 101250- (2023)
Purpose: Compared with photon-based techniques, proton beam radiation therapy (PBT) may improve the therapeutic ratio of radiation therapy (RT) for locally advanced pancreatic cancer (LAPC), but available data have been limited to single-institutiona
Externí odkaz:
https://doaj.org/article/5974ac5f635146098c27e46c38db1a87
Autor:
Jacob S. Parzen, William Hartsell, John Chang, Smith Apisarnthanarax, Jason Molitoris, Michael Durci, Henry Tsai, James Urbanic, Jonathan Ashman, Carlos Vargas, Craig Stevens, Peyman Kabolizadeh
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-8 (2020)
Abstract Background Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target
Externí odkaz:
https://doaj.org/article/ea11d4a3bb2e4bb0bedb2b0579bb64a0
Autor:
Craig W. Stevens, Henry Tsai, Carlos Vargas, Michael Durci, Smith Apisarnthanarax, Peyman Kabolizadeh, William F. Hartsell, Jason K. Molitoris, James J. Urbanic, Jonathan B. Ashman, John Chang, Jacob S Parzen
Publikováno v:
Radiation Oncology (London, England)
Radiation Oncology, Vol 15, Iss 1, Pp 1-8 (2020)
Radiation Oncology, Vol 15, Iss 1, Pp 1-8 (2020)
Background Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target volume wh
Autor:
Sanford R. Katz, Hunter Boggs, Sahaja Acharya, Lane R. Rosen, Michael Durci, Benjamin W. Fischer-Valuck
Publikováno v:
Tumori Journal. 101:287-293
Introduction Histological confirmation of non-small cell lung cancer (NSCLC) is often required before patients are offered stereotactic body radiation therapy (SBRT) as a treatment option. Many patients, however, are unsuitable to undergo a biopsy pr
Autor:
Benjamin W, Fischer-Valuck, Michael, Durci, Sanford R, Katz, Hsinshun Terry, Wu, Joseph, Syh, Jarron, Syh, Bijal, Patel, Lane R, Rosen
Publikováno v:
Thoracic cancer. 4(1)
To determine the influence of patient and tumor characteristics on clinical outcomes in patients with early-stage non-small cell lung cancer (NSCLC) treated with helical intensity modulated stereotactic body radiotherapy (SBRT). From March 2005 to Au
Autor:
Amol Takalkar, Michael Durci, Sanford R. Katz, Lane R. Rosen, Mansour Mirfakhraee, Benjamin W. Fischer-Valuck, David Lillian, Hsinshun Terry Wu
Publikováno v:
Journal of Radiation Oncology. 3:379-386
Objective This study aimed to characterize clinical outcomes with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) scan results at different follow-up time points following stereotactic body radiation therapy (SB
Autor:
Joseph Syh, Jarron Syh, Hsinshun Terry Wu, Lane R. Rosen, Benjamin W. Fischer-Valuck, Michael Durci, Sanford R. Katz, Bijal Patel
Publikováno v:
Thoracic Cancer. 4:27-34
Background: To determine the influence of patient and tumor characteristics on clinical outcomes in patients with early-stage non-small cell lung cancer (NSCLC) treated with helical intensity modulated stereotactic body radiotherapy (SBRT). Methods:
Autor:
Lane R Rosen, Benjamin W Fischer-Valuck, Sanford R Katz, Michael Durci, Hsinshun Terry Wu, Joseph Syh, Jarron Syh, Bijal Patel
Publikováno v:
Tumori. 100(1)
Our aim is to report on the clinical methods and outcomes of helical intensity-modulated stereotactic body radiotherapy (SBRT) for the treatment of early-stage non-small cell lung cancer (NSCLC).Seventy-nine patients with stage I NSCLC underwent heli
Autor:
Chenelle, Slepicka, Michael, Durci
Publikováno v:
The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society. 164(2)
Primary cardiac angiosarcoma is a rare and aggressive tumor with a remarkably high rate of metastasis. Due to the high rate of metastasis, surgical resection is often limited and survival expectations modest. This report describes the case of a 35-ye
Autor:
Clifton Frilot, Lane R. Rosen, R. A. Lacour, Joseph Syh, Terry Wu, Addison B. Willett, J. Ben Wilkinson, Michael Durci, Destin R. Black, Sanford R. Katz
Publikováno v:
Brachytherapy. 13:S89-S90